Glioblastoma in Patients over 70 Years of Age.

Radiology and Oncology
Uros SmrdelAles Smrdel

Abstract

Glioblastoma has in last 20 years seen the steady increase of incidence, which is most prominent in the group of older patients. These older than 70 years have significantly poorer prognosis than other patients and are considered a distinct group of glioblastoma patients. Modified prognostic factors are being used in these patients and this information is lately supplemented with the genetic and epigenetic information on tumour. The therapy is now often tailored accordingly. The aim of our study was to analyse the current treatment of the glioblastoma patients over 70 years of age to determine the impact of clinical prognostic factors. Among patients treated at the Institute of Oncology Ljubljana between 1997 and 2015, we found that 207 were older than 70 years. We analysed their survival, clinical prognostic factors (age, performance status) treatment modalities (extent of surgery, radiation dose, chemotherapy). Median survival of patients older than 70 years was 5.3 months which was statistically significant inferior to the survival of younger patients (p < 0.001). The clinical prognostic factors that influenced survival the most were performance status (p < 0.001), extent of surgical resection (p < 0.001), addition of temozo...Continue Reading

References

Jan 1, 1996·Cancer Investigation·A D SteinfeldI Walker
Dec 4, 2003·International Journal of Cancer. Journal International Du Cancer·Stefan LönnMaria Feychting
Oct 7, 2004·Cancer Research·Hiroko OhgakiPaul Kleihues
Apr 13, 2007·The New England Journal of Medicine·Florence Keime-GuibertUNKNOWN Association of French-Speaking Neuro-Oncologists
Mar 3, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ramandeep S AroraJillian M Birch
Oct 5, 2010·International Journal of Radiation Oncology, Biology, Physics·Jing LiMinesh P Mehta
Oct 15, 2013·Expert Review of Neurotherapeutics·Alba FiorentinoVincenzo Fusco
Mar 4, 2014·Radiology and Oncology·Uros SmrdelMatjaz Zwitter
Mar 5, 2014·Clinical Interventions in Aging·Nils D Arvold, David A Reardon
Mar 4, 2015·Bulletin du cancer·Julian BiauPierre Verrelle
May 16, 2015·The American Journal of Pathology·Ines CrespoMaria Dolores Tabernero
Jun 16, 2015·World Neurosurgery·Randy S D'AmicoGuy M McKhann

❮ Previous
Next ❯

Citations

Jan 21, 2019·Radiology and Oncology·Janez SimencMetoda Lipnik-Stangelj
Jun 5, 2020·Neurosurgical Review·Johannes WachMatthias Schneider
Aug 20, 2019·Journal of Neuro-oncology·Menha SwellamSamy B Said
Feb 19, 2021·International Journal of Radiation Oncology, Biology, Physics·Yi LaoKe Sheng
Jun 3, 2021·Neurology International·Omar Al-TaeiTariq Al-Saadi
Jun 29, 2021·Frontiers in Oncology·Johannes WachErdem Güresir

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical
biopsy
surgical resection

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.